N@N

Sernova Corp.: Appointment of Dr. Philip M. Toleikis to the Sernova Board of Directors

^{Published on 2009-06-29 14:58:06, Last Modified on 2009-06-29 14:58:34 - Market Wire}
 

LONDON, ONTARIO--(Marketwire - June 29, 2009) - Sernova Corp. (TSX VENTURE:SVA)

Dr. George Adams, Chairman of the Board of Directors of Sernova Corp. is pleased to announce the appointment of Dr. Philip Toleikis to the Corporation's Board of Directors. Dr. Toleikis was previously appointed as President and Chief Executive Officer of Sernova on April 28, 2009. In making the appointment, Dr. Adams said "Dr. Toleikis is now a key element in Sernova's future success, and it is important going forward to utilize his extensive scientific and business knowledge and expertise at the Board level. On behalf of the Corporation's shareholders and the other Board members, I would like to welcome him to the Board."

About Sernova

Sernova Corp. is a Canadian-based, health-sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin-dependent diabetes, using its patented Sertolin cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.